Neurexis Therapeutics is focused on developing innovative neuroprotective therapies to address the significant health challenges posed by conditions such as stroke and cardiac arrest. Their lead product, tatCN19o, is a 30 amino acid peptide designed to mitigate neuronal damage following ischemic events. This peptide features two functional domains: one that enhances its ability to cross cell membranes and the blood-brain barrier, and another that acts as a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII), a key target for neuroprotection. Preclinical studies have demonstrated tatCN19o's efficacy in various animal models, showing neuroprotective effects after cardiac arrest and ischemic stroke, as well as its compatibility with standard therapeutic hypothermia.

The safety profile of tatCN19o is promising, with no acute adverse effects observed in high-dose studies across different animal models, including mice and pigs. Pharmacokinetic studies indicate a suitable half-life for clinical application, and in vitro analyses have shown no off-target binding or negative impacts on memory function. Neurexis holds four issued US patents for tatCN19o and is currently advancing its preclinical development, aiming to provide a much-needed therapeutic option for patients suffering from the long-term consequences of ischemic brain injuries.

United States

Neurexis is developing an optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia.

Neurexis Therapeutics

Company Details